[PET and digestive cancers].
In digestive oncology, the most frequent indication for FDG PET, in our experience and as reported in the literature, is the localisation of recurrent colorectal cancer. This molecular imaging method has also been shown to be clinically useful in various other settings, especially for preoperative staging, for colorectal, esophageal, gastric, pancreatic, hepatic and biliary cancers. We also report on current PET practice in two particular cancers: hepatocellular carcinoma, for which other tracers, including fluoromethylcholine-(18F), are being currently evaluated, and gastrointestinal endocrine tumours, which are included in the recent French marketing authorisation of fluoroDOPA-(18F) and which are also potential targets for radiolabelled somatostatin analogues for PET imaging.
Talbot
Jean-Noël
JN
Service de médecine nucléaire, AP-HP, Hôpital Tenon, F-75020 Paris, France. jean-noel.talbot@tnn.aphp.fr
Montravers
Françoise
F
Gutman
Fabrice
F
Kerrou
Khaldoun
K
Huchet
Virginie
V
Grahek
Dany
D
Andre
Thierry
T
Houry
Sydney
S
Touboul
Emmanuel
E
Rosmorduc
Olivier
O
Poupon
Raoul
R
Ruszniewski
Philippe
P
Rougier
Philippe
P
Grange
Jean-Didier
JD
D004067:Digestive System Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18